Technology Videos

NEJM Clinician: Catheter-Directed PE Treatment: Does It Deliver?

The New England Journal of Medicine reports a multinational randomized trial evaluating catheter‑directed fibrinolysis (CDT) versus standard anticoagulation in patients with intermediate‑risk (sub‑massive) pulmonary embolism. Over 500 participants were assigned to low‑dose, catheter‑delivered clot‑busting therapy or anticoagulation alone, with the primary composite endpoint of life‑threatening decompensation—including cardiac arrest, shock, or mechanical ventilation. Results showed a 4% incidence of the primary endpoint in the CDT arm compared with 10% in the anticoagulation group, translating to a number‑needed‑to‑treat of 17 to prevent one decompensation event. Importantly, the trial documented no statistically significant rise in major bleeding or intracranial hemorrhage among patients receiving catheter‑directed therapy. The presenter emphasized a straightforward clinical takeaway: when faced with an intermediate‑risk PE and concern for deterioration, there is no reason to delay referral to the cath lab. The data suggest that early intervention can markedly improve outcomes without added safety concerns. If adopted broadly, these findings could reshape PE management algorithms, encouraging earlier use of minimally invasive CDT and potentially influencing guideline updates and hospital protocols worldwide.